110238-61-4

Usage

Uses

Used in Organic Synthesis:
O-(cyclohexylmethyl)hydroxylamine is utilized as a reagent in organic synthesis for its capacity to participate in a range of chemical reactions, contributing to the formation of diverse organic compounds.
Used in Corrosion Inhibition:
In industrial processes, O-(cyclohexylmethyl)hydroxylamine serves as a corrosion inhibitor, leveraging its ability to form stable metal complexes to protect metal surfaces from degradation and corrosion.
Used in Pharmaceutical Industry:
O-(cyclohexylmethyl)hydroxylamine is explored as a pharmaceutical intermediate due to its potential role in the synthesis of various medicinal compounds, highlighting its importance in drug development.
Used in Specialty Chemicals Production:
O-(cyclohexylmethyl)hydroxylamine also acts as a reagent in the production of specialty chemicals, where its unique properties are harnessed to create specific high-value products.
It is crucial to handle O-(cyclohexylmethyl)hydroxylamine with care, adhering to safety guidelines to mitigate any potential hazards associated with its use.

Upstream product

• 2550-36-9 Cyclohexylmethyl bromide 
• 113211-23-7 2-(cyclohexylmethoxy)-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 252872-74-5 N₁-(cyclohexylmethoxy)-4-methoxy-1-benzenesulfonamide 
• 880471-97-6 C₁₇H₂₂ClF₃N₂O₃S 
• 880472-04-8 C₁₈H₂₄ClF₃N₂O₃S 
• 1170231-80-7 N-(cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-hexanesulfonamide 
• 1170235-36-5 6-(2-cyano-1-(pyridin-4-yl)guanidino)-N-(cyclohexylmethoxy)hexane-1-sulfonamide 
• 1170236-88-0 6-(2-cyano-1-(pyridin-4-yl)guanidino)-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)hexane-1-sulfonamide 
• 1170232-49-1 6-amino-N-(cyclohexylmethoxy)-N-(2-fluoroethyl)-1-hexanesulfonamide 
• 1170231-67-0 6-amino-N-(cyclohexylmethoxy)hexane-1-sulfonamide 
• 219778-43-5 5-bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 

Relevant academic research and scientific papers

Method for synthesizing azanol

The invention relates to a hydroxylamine synthesis method. The hydroxylamine synthesis method comprises the following steps: (A) enabling alcohol to react with alkyl sulfonyl halide in the presence of an acid-binding agent to obtain sulphonate; (B) enabling the obtained sulphonate in the step (A) to react with N-hydroxycyclodiimide in the presence of alkali to generate alkylate of the N-hydroxycyclodiimide; and (C) enabling the alkylate obtained in the step (B) to react with an aminolysis reagent or a hydrazinolysis reagent to obtain the hydroxylamine. The method is high in yield and suitable for large-scale industrial hydroxylamine synthesis.

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship

Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. By using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is described, and the compounds are optimized. Compounds are designed inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds. In comparison with recently published derivatives, the new analogues exhibit an equally potent antiproliferative activity in vitro and comparable activity in vivo. The best performing compounds from these series showed subnanomolar antiproliferative activity toward a series of cancer cell lines (compound 15: IC50 0.025 and 0.33 nM, in A2780 (ovarian carcinoma) and MCF-7 (breast), respectively) and potent antitumor in vivo activity in well-tolerated doses in a xenograft model. In an A2780 xenograft mouse model with large tumors (500 mm3), compound 15 reduced the tumor volume to one-fifth of the starting volume at a dose of 3 mg/kg administered ip, bid, days 1-9. Thus, compounds found in this study compared favorably with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.

Parasiticidal 2-alkoxy- and 2-aryloxyiminoalkyl trifluoromethanesulfonanilides

A series of novel 2-alkoxy- and 2-aryloxyiminoalkyl trifluoromethanesulfonanilide derivatives have shown significant in vitro parasiticidal activity against the ectoparasites Ctenocephalides felis and Rhipicephalus sanguineus. A number of these compounds also displayed significant in vitro endoparasite activity against the nematode Haemonchus contortus. Crown Copyright

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been identified as potent MEK inhibitors. 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzam ide, CI-1040, was the first MEK inhibitor to demonstrate in vivo activity in preclinical animal models and subsequently became the first MEK inhibitor to enter clinical trial. CI-1040 suffered however from poor exposure due to its poor solubility and rapid clearance, and as a result, development of the compound was terminated. Optimization of the diphenylamine core and modification of the hydroxamate side chain for cell potency, solubility, and exposure with oral delivery resulted in the discovery of the clinical candidate N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-b enzamide PD 0325901.

Hydrazide and alkoxyamide angiogenesis inhibitors

Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.